Quinton Meek, MD | |
65 Old Sprinfield Rd., Lebanon, KY 40033 | |
(270) 692-2509 | |
(270) 692-2592 |
Full Name | Quinton Meek |
---|---|
Gender | Male |
Speciality | Psychiatry & Neurology - Psychiatry |
Location | 65 Old Sprinfield Rd., Lebanon, Kentucky |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1912952458 | NPI | - | NPPES |
000000352019 | Other | KY | ANTHEM |
11304796 | Other | CAQH | |
30605018 | Medicaid | KY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 28887 (Kentucky) | Primary |
Mailing Address | Practice Location Address |
---|---|
Quinton Meek, MD 107 Cranes Roost Ct, Elizabethtown, KY 42701-3650 Ph: (270) 765-2605 | Quinton Meek, MD 65 Old Sprinfield Rd., Lebanon, KY 40033 Ph: (270) 692-2509 |
News Archive
Vitamin D deficiency puts patients with Inflammatory Bowel Disease (IBD) at greater risk of osteoporosis, osteopenia and an overall higher rate of abnormal bone density, according to the results of a new study unveiled today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.
Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.
Pulmonary fibrosis can possibly be attributed to a kind of cellular aging process, which is called senescence. This has been shown by researchers from the Helmholtz Zentrum München, partner in the German Center for Lung Research.
Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea. Researchers are working with biotechnology company, Provexis, to test a new plantain based food product that could treat patients with the disease.
Celgene Corporation today announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.
› Verified 6 days ago